Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.

CONCLUSION: AMBER will define the ability of patiromer to facilitate the use of spironolactone, an effective antihypertensive therapy for patients with RHTN and CKD. PMID: 30176673 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30176673?dopt=Abstract

Source: American Journal of Nephrology - September 3, 2018 Category: Urology & Nephrology Authors: Agarwal R, Rossignol P, Garza D, Mayo MR, Warren S, Arthur S, Romero A, White WB, Williams B Tags: Am J Nephrol Source Type: research